母细胞性浆细胞样树突状细胞肿瘤（BPDCN）：市场展望、流行病学、竞争格局、市场预测报告（2025-2035年）

市场概览

• 法国市场预计将从约 830 万美元成长到约 1,740 万美元（年复合成长率约 7-8%）。
• 虽然患者人数不多，但由于标靶治疗和诊断技术的进步，预计患者人数将会成长。

浆细胞样树突状细胞肿瘤（BPDCN）概述

浆细胞样树突状细胞肿瘤（BPDCN）是一种罕见的、侵袭性强的骨髓恶性肿瘤，预后不良，起源于浆细胞样树突状细胞前驱细胞。最常见的症状是皮肤浸润，患者通常表现为无症状的皮损，从胎记到斑块和结节不等，常涉及大面积皮肤。

除了皮肤外，BPDCN 也常扩散至骨髓、淋巴结、脾臟和中枢神经系统 (CNS)，引起包括血球减少和器官浸润在内的全身性病变。此病属于树突状细胞和组织细胞肿瘤，常与其他血液系统恶性肿瘤相关或进展为其他骨髓恶性肿瘤。

此疾病主要影响老年人，男性患者较多（男女比例约3:1至5:1）。通常在60至70岁之间确诊。儘管治疗方法有所进步，但由于其侵袭性强、復发率高且长期治疗选择有限，BPDCN仍然是一种临床上具有挑战性的疾病。

主要亮点

• BPDCN 是一种罕见且侵袭性强的骨髓恶性肿瘤，存在着巨大的未满足医疗需求。
• 预计美国病例数将从约 1800 例增加到约 2400 例（年复合成长率约 3%）。

格式化和更新讯息

• 详细报告（PDF）
• 市场预测模型（基于微软Excel）
• 流行病学数据（MS Excel，互动式工具）
• 高阶主管洞察（PPT简报）
• 其他功能：定期更新、自订和顾问支援。
• 根据 Thelansis 的政策，我们确保所有最新更新在发布前都反映在报告内容和市场模型中。

主要问题

• 我们如何优化 G8 市场（美国、欧盟 5 国、日本、中国）的药物开发与生命週期管理策略？
• 从发病率、盛行率、人群组成以及接受药物治疗的患者人数来看，患者数量分别是多少？
• 未来十年市场收入和病患份额的预测是多少？
• 哪些因素对市场趋势影响最大？
• 受访专家对目前和新兴的治疗方法有何看法？
• 哪款在研发线产品最有前景？其上市潜力及未来市场定位如何？
• 主要未被满足的需求是什么？ KOL 对目标受众有何期望？
• 为确保药物核准并顺利进入市场，必须满足哪些关键的监管和支付方要求？

目标国家

• G8
  • 我们
  • EU5
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
  • 日本
  • 中国

大公司

• Chongqing Precision Biotech Co. Ltd
• AbbVie
• Stemline Therapeutics

目录

第一章：主要调查结果及分析师说明

• 主要趋势：市场概况、SWOT分析、商业性利益与风险等。

第二章：疾病背景

• 疾病定义、分类、病因和病理生理学、药物标靶等。

第三章：流行病学

• 重点
• 发病率/盛行率
• 已确诊并接受药物治疗的患者人数
• 合併症
• 其他相关患者群

第四章 市场规模及预测

• 重点
• 市场驱动因素与限制因素
• 按药物类别分類的趋势
• 各国具体趋势

第五章 竞争情势

• 目前的治疗方法
  • 重点
  • 诊断和治疗过程/演算法
  • 主要治疗方法概述及KOL洞察
• 新兴治疗方法
  • 重点
  • 值得关注的后期新治疗方法－概述、市场上市预期及KOL洞察
  • 值得关注的早期研发管线

第六章：未满足的需求与TPP分析

• 主要未满足的需求以及透过新兴治疗方法实现的未来可能性
• TPP分析与KOL展望

第七章 监理与报销环境

第八章附录

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Outlook

Thelansis's "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Blastic Plasmacytoid Dendritic Cell Neoplasm treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Overview

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy with a poor prognosis, arising from precursors of plasmacytoid dendritic cells. It most commonly presents with cutaneous involvement, where patients develop asymptomatic lesions ranging from bruise-like patches to plaques or nodules, often involving large body areas.

Beyond the skin, BPDCN frequently involves the bone marrow, lymph nodes, spleen, and central nervous system (CNS), leading to systemic disease manifestations including cytopenias and organ infiltration. It is classified under dendritic cell and histiocytic neoplasms and is often associated with or evolves into other hematologic malignancies.

The disease predominantly affects older adults, with a strong male predominance (male-to-female ratio ~3:1 to 5:1), and is typically diagnosed between 60-70 years of age. Despite advances, BPDCN remains clinically challenging due to its aggressive nature, high relapse rates, and limited long-term treatment options.

Key Highlights

• BPDCN is a rare, aggressive hematologic malignancy with high unmet need
• US incidence expected to increase from ~1.8K to ~2.4K (~3% CAGR)

Market Overview

• France market projected to grow from ~$8.3M to ~$17.4M (~7-8% CAGR)
• Growth driven by targeted therapies and improved diagnosis, despite small patient population

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Chongqing Precision Biotech Co. Ltd
• AbbVie
• Stemline Therapeutics

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)